Christian Von der Brelie1, Michael Seifert2, Sergej Rot3, Anja Tittel4, Carsten Sanft2, Ullrich Meier3, Johannes Lemcke3. 1. Department of Neurosurgery, University of Göttingen, Göttingen, Germany; Department of Neurosurgery, Unfallkrankenhaus Berlin, Berlin, Germany. Electronic address: cvdb@gmx.net. 2. Department of Anesthesiology, Unfallkrankenhaus Berlin, Berlin, Germany. 3. Department of Neurosurgery, Unfallkrankenhaus Berlin, Berlin, Germany. 4. Department of Radiology, Unfallkrankenhaus Berlin, Berlin, Germany.
Abstract
BACKGROUND: Ketamine has neuroprotective characteristics as well as beneficial cardiocirculatory properties and may thus reduce vasopressor consumption. In contrast, sedation with ketamine (like any other sedative drug) has side effects. This study assesses the influence of ketamine on intracranial pressure (ICP), on the consumption of vasopressors in induced hypertension therapy, and on the occurrence of delayed cerebral ischemia (DCI)-associated cerebral infarctions, with particular focus on the complications of sedation in patients with aneurysmal subarachnoid hemorrhage (SAH). METHODS: This is a retrospective, observational study. Sixty-five patients with SAH who underwent a period of sedation were included. The clinical course variables (Richmond Agitation and Sedation scale score, ICP values, consumption of vasopressors, complications of sedation, outcome, and other clinical parameters) were analyzed. Cranial computed tomography results were analyzed. RESULTS: Forty-one patients underwent sedation including ketamine (63.1%). Ketamine decreased the ICP in 92.7% of the cases. Vasopressors was reduced in 53.6%. DCI-associated cerebral infarctions occurred significantly less often in the patient cohort being treated with sedation including ketamine (7.3% vs. 25% in the nonketamine group; P = 0.04). The rate of major complications was not higher in the ketamine group. Outcome was not different regarding the groups if they were sedated with or without ketamine. CONCLUSIONS: Ketamine decreases the ICP and is not associated with a higher rate of complications. The rate of DCI-associated cerebral infarctions was lower in the ketamine group. Ketamine administration led to a reduction of vasopressors used for induced hypertension.
BACKGROUND:Ketamine has neuroprotective characteristics as well as beneficial cardiocirculatory properties and may thus reduce vasopressor consumption. In contrast, sedation with ketamine (like any other sedative drug) has side effects. This study assesses the influence of ketamine on intracranial pressure (ICP), on the consumption of vasopressors in induced hypertension therapy, and on the occurrence of delayed cerebral ischemia (DCI)-associated cerebral infarctions, with particular focus on the complications of sedation in patients with aneurysmal subarachnoid hemorrhage (SAH). METHODS: This is a retrospective, observational study. Sixty-five patients with SAH who underwent a period of sedation were included. The clinical course variables (Richmond Agitation and Sedation scale score, ICP values, consumption of vasopressors, complications of sedation, outcome, and other clinical parameters) were analyzed. Cranial computed tomography results were analyzed. RESULTS: Forty-one patients underwent sedation including ketamine (63.1%). Ketamine decreased the ICP in 92.7% of the cases. Vasopressors was reduced in 53.6%. DCI-associated cerebral infarctions occurred significantly less often in the patient cohort being treated with sedation including ketamine (7.3% vs. 25% in the nonketamine group; P = 0.04). The rate of major complications was not higher in the ketamine group. Outcome was not different regarding the groups if they were sedated with or without ketamine. CONCLUSIONS:Ketamine decreases the ICP and is not associated with a higher rate of complications. The rate of DCI-associated cerebral infarctions was lower in the ketamine group. Ketamine administration led to a reduction of vasopressors used for induced hypertension.
Authors: Fawaz Al-Mufti; Stephan A Mayer; Gurmeen Kaur; Daniel Bassily; Boyi Li; Matthew L Holstein; Jood Ani; Nicole E Matluck; Haris Kamal; Rolla Nuoman; Christian A Bowers; Faizan S Ali; Hussein Al-Shammari; Mohammad El-Ghanem; Chirag Gandhi; Krishna Amuluru Journal: Neuroradiol J Date: 2021-09-03
Authors: R David Andrew; Eszter Farkas; Jed A Hartings; K C Brennan; Oscar Herreras; Michael Müller; Sergei A Kirov; Cenk Ayata; Nikita Ollen-Bittle; Clemens Reiffurth; Omer Revah; R Meldrum Robertson; Ken D Dawson-Scully; Ghanim Ullah; Jens P Dreier Journal: Neurocrit Care Date: 2022-02-22 Impact factor: 3.532
Authors: Patrick M Honore; Aude Mugisha; Luc Kugener; Sebastien Redant; Rachid Attou; Andrea Gallerani; David De Bels Journal: Crit Care Date: 2020-06-18 Impact factor: 9.097
Authors: Silvia Hernández-Durán; Clara Salfelder; Joern Schaeper; Onnen Moerer; Veit Rohde; Dorothee Mielke; Christian von der Brelie Journal: Neurocrit Care Date: 2021-02 Impact factor: 3.210
Authors: Katalina Chan; Lisa D Burry; Christopher Tse; Hannah Wunsch; Charmaine De Castro; David R Williamson Journal: Ann Pharmacother Date: 2022-01-26 Impact factor: 3.463